I'm not sure I could contradict the results of the capacity report that was commissioned. We were surprised, though. Dr. Carver and I have been in drug development for eight years. We had compounds in clinical trials. We commissioned manufacturing for clinical trial lots. There are some issues that come up when you talk about capacity: are you dealing with theoretical capacity or are you dealing with commercial capacity? So when you're talking about commercial capacity, this industry is a very low margin business and needs high volume.
To manufacture clinical lots at a pilot scale is uneconomic, generally speaking. So when the report questions organizations about whether they have theoretical capacity, we would think most of the respondents would say yes. To us, though, when you're running clinical trials, the GMP requirements are such that if you produce a clinical pilot scale run, you probably want to produce it in the same facility at a commercial scale. That's why I think in our organization our application was designed on developing a commercial scale, because you want to curtail the transition between pilot scale lots and commercial production.